Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 5, 2011, Pages 740-750

  González, Raúl ^a,e   Cruz, Adolfo ^b,e   Ferrín, Gustavo ^a,e   López Cillero, Pedro ^a,e   Briceño, Javier ^a,e   Gómez, Miguel A ^c   Rufián, Sebastián ^a,e   Padillo, Javier ^c,e   De La Mata, Manuel ^a,e   Marin, Jose J G ^d,e   Muntane, Jordi ^a,e  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Valle de Los Pedroches General Hospital   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d UNIVERSITY OF SALAMANCA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cholestasis; Cytochrome P450; Glucuronosyltransferase; Hepatocytes; Nuclear receptor

Indexed keywords

BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; GLUCURONOSYLTRANSFERASE; LIPID TRANSFER PROTEIN; MULTIDRUG RESISTANCE PROTEIN 4; POLYPEPTIDE; RIFAMPICIN; UDP GLUCURONOSYLTRANSFERASE 2B4; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT OBSTRUCTION; CELL PROTECTION; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL DAMAGE; LIVER PROTECTION; MALE; METABOLIC REGULATION; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM;

ANIMALS; APOPTOSIS; BILE ACIDS AND SALTS; CARRIER PROTEINS; CELLS, CULTURED; CHOLESTASIS; DISEASE MODELS, ANIMAL; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; GLYCOCHENODEOXYCHOLIC ACID; HEPATECTOMY; HEPATOCYTES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; RIFAMPIN; RNA, MESSENGER;

EID: 80052531403     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-011-0396-3     Document Type: Article

References (46)

1. Starzl TE, Demetris AJ, Van TD. Liver transplantation (1). N Engl J Med. 1989;321:1014-22.
2. Hofmann AF. Chemistry and enterohepatic circulation of bile acids. Hepatology. 1984;4:4S-14S. (Pubitemid 14018137)
3. Galle PR, Theilmann L, Raedsch R, et al. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology. 1990;12:486-91. (Pubitemid 20382016)
4. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest. 1994;94:2183-92. (Pubitemid 24379587)
5. Mitchison DA. The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med. 2005;171: 699-706. (Pubitemid 40471139)
6. Gillespie DA, Vickers CR. Pruritus and cholestasis: therapeutic options. J Gastroenterol Hepatol. 1993;8:168-73. (Pubitemid 23085549)
7. Berg CL, Gollan JL. Primary biliary cirrhosis: new therapeutic directions. Scand J Gastroenterol Suppl. 1992;192:43-9.
8. Cancado EL, Leitao RM, Carrilho FJ. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol. 1998;93:1510-7. (Pubitemid 29075191)
9. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 1991;99:465-71.
10. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50:436-9. (Pubitemid 34161065)
11. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm. 1996;24:449-59. (Pubitemid 27156931)
12. Schoene B, Fleischmann RA, Remmer H, et al. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur J Clin Pharmacol. 1972;4:65-73.
13. Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol. 1985;28:475-7. (Pubitemid 15063822)
14. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006;5:3.
15. Muntane J. Regulation of drug metabolism and transporters. Curr Drug Metab. 2009;10:932-45.
16. Lim YP, Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet. 2008;23:14-21.
17. Pascussi JM, Gerbal-Chaloin S, Drocourt L, et al. The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors. Biochim Biophys Acta. 2003;1619:243-53. (Pubitemid 36163419)
18. Rae JM, Johnson MD, Lippman ME, et al. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001;299:849-57. (Pubitemid 33104951)
19. Soars MG, Petullo DM, Eckstein JA, et al. An assessment of udpglucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos. 2004;32:140-8. (Pubitemid 38112546)
20. Dilger K, Greiner B, Fromm MF, et al. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6. Pharmacogenetics. 1999;9:551-9.
21. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14581-7.
22. Frank C, Makkonen H, Dunlop TW, et al. Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J Mol Biol. 2005;346: 505-19.
23. Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229-36.
24. Ehret MJ, Levin GM, Narasimhan M, et al. Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol. 2007;22:49-53. (Pubitemid 46178778)
25. Monte MJ, Marin JJ, Antelo A, et al. Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol. 2009; 15:804-16.
26. Pichard L, Raulet E, Fabre G, et al. Human hepatocyte culture. Methods Mol Biol. 2006;320:283-93.
27. Gonzalez R, Collado JA, Nell S, et al. Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured d-galactosamine- treated human hepatocytes. Free Radic Biol Med. 2007;43:1439-52. (Pubitemid 47542364)
28. Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol. 2009;15:1677-89.
29. Yerushalmi B, Dahl R, Devereaux MW, et al. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology. 2001;33:616-26. (Pubitemid 32185224)
30. Sokol RJ, McKim JM Jr, Goff MC, et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology. 1998; 114:164-74. (Pubitemid 28020966)
31. Soden JS, Devereaux MW, Haas JE, et al. Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. Hepatology. 2007;46:485-95. (Pubitemid 47344784)
32. Menke JG, Macnaul KL, Hayes NS, et al. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002;143:2548-58. (Pubitemid 34701318)
33. Martinez-Jimenez CP, Jover R, Donato MT, et al. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab. 2007;8:185-94. (Pubitemid 46218685)
34. Marschall HU, Wagner M, Zollner G, et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology. 2005;129:476-85. (Pubitemid 41096635)
35. Hinson JA, Forkert PG. Phase II enzymes and bioactivation. Can J Physiol Pharmacol. 1995;73:1407-13. (Pubitemid 26024399)
36. Jung D, Mangelsdorf DJ, Meyer UA. Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem. 2006;281:19081-91. (Pubitemid 44035412)
37. Zhang J, Huang W, Qatanani M, et al. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J Biol Chem. 2004; 279:49517-22. (Pubitemid 39625839)
38. Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33:633-46. (Pubitemid 32185226)
39. Shoda J, Kano M, Oda K, et al. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliaty secretory function. Am J Gastroenterol. 2001; 96:3368-78. (Pubitemid 34016662)
40. Oswald M, Kullak-Ublick GA, Paumgartner G, et al. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver. 2001;21:247-53. (Pubitemid 32677380)
41. Zollner G, Fickert P, Silbert D, et al. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38:717-27. (Pubitemid 36613336)
42. Elferink MG, Olinga P, Draaisma AL, et al. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttrancriptional process. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1008-16. (Pubitemid 39423693)
43. Geier A, Zollner G, Dietrich CG, et al. Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. Hepatology. 2005;41:470-7. (Pubitemid 40289493)
44. Watanabe N, Takashimizu S, Kojima S, et al. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol Res. 2007;37:598-607. (Pubitemid 47009245)
45. Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem. 2001; 276:28857-65.
46. Kast HR, Goodwin B, Tarr PT, et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem. 2002;277:2908-15. (Pubitemid 34953324)